Alaeddine Mohamad, Bhat Deepti P, Pohlman Joshua, Graziano Joseph, Gooty Vasu, Sicim Hüseyin, Velez Daniel A
Cardiothoracic Surgery and Fontan Clinic, Phoenix Children's Hospital, and University of Arizona, Phoenix, Ariz.
JTCVS Tech. 2025 May 3;31:133-141. doi: 10.1016/j.xjtc.2025.04.013. eCollection 2025 Jun.
Protein-losing enteropathy is among the most debilitating complications of Fontan circulation. Central venous hypertension increases lymphatic pressure in the thoracic duct, potentially leading to significant intestinal protein loss. Current treatment options for recurrent or refractory protein-losing enteropathy are limited to complex lymphatic interventions, fenestration creation, and heart transplantation. We have implemented an alternative surgical approach-thoracic duct decompression-and report our early experience in pediatric Fontan patients.
We studied 5 Fontan patients, analyzing their preoperative history, treatment, and surgical approach tailored to their unique anatomy, postoperative course, and symptoms at their most recent Fontan clinic follow-up.
Since February 2024, 5 Fontan patients aged 5 to 16 years diagnosed with recurrent protein-losing enteropathy underwent surgical thoracic duct decompression. The first 2 patients experienced mild anastomotic narrowing, which was successfully treated with transcatheter angioplasty. The remaining 3 patients had uneventful postoperative course and hospital stays of approximately 1 week. All patients were closely monitored with echocardiograms and laboratory testing. At 6 months postoperatively, all remained symptom-free and transplant-free (follow-up range, 7-12 months), and reported improved quality of life. No cases of turndown stenosis were observed. Additionally, all patients were successfully weaned off enteral steroids and aggressive diuretic therapy. A mild decrease in oxygen saturations (1%-3%) was noted with no clinical significance.
Thoracic duct decompression appears to be a feasible intervention for recurrent protein-losing enteropathy in Fontan patients, demonstrating a low rate of short-term complications. This procedure may serve as a viable alternative to heart transplantation in select cases; however, its long-term efficacy warrants further investigation.
蛋白丢失性肠病是Fontan循环最使人衰弱的并发症之一。中心静脉高压会增加胸导管内的淋巴压力,可能导致大量肠道蛋白丢失。目前针对复发性或难治性蛋白丢失性肠病的治疗选择仅限于复杂的淋巴干预、开窗术和心脏移植。我们实施了一种替代性手术方法——胸导管减压术,并报告我们在小儿Fontan患者中的早期经验。
我们研究了5例Fontan患者,分析了他们的术前病史、治疗情况以及根据其独特解剖结构量身定制的手术方法、术后病程以及他们在最近一次Fontan门诊随访时的症状。
自2024年2月以来,5例年龄在5至16岁、被诊断为复发性蛋白丢失性肠病的Fontan患者接受了胸导管减压手术。前2例患者出现轻度吻合口狭窄,经导管血管成形术成功治疗。其余3例患者术后病程平稳,住院时间约1周。所有患者均通过超声心动图和实验室检查进行密切监测。术后6个月时,所有患者均无症状且无需进行移植(随访范围为7至12个月),并报告生活质量有所改善。未观察到缩窄性狭窄病例。此外,所有患者均成功停用肠内类固醇和积极的利尿治疗。氧饱和度出现轻度下降(1%-3%),但无临床意义。
胸导管减压术似乎是Fontan患者复发性蛋白丢失性肠病的一种可行干预措施,短期并发症发生率较低。在某些情况下,该手术可能是心脏移植的一种可行替代方法;然而,其长期疗效有待进一步研究。